Abstract

The voltage-gated sodium (NaV) channel NaV1.7 has been identified as a potential novel analgesic target due to its involvement in human pain syndromes. However, clinically available NaV channel blocking drugs are not selective among the nine NaV channel subtypes, NaV1.1-NaV1.9. Moreover, the two currently known classes of NaV1.7 subtype-selective inhibitors (aryl- and acylsulfonamides) have undesirable characteristics that may limit their development. To this point understanding of the structure-activity relationships of the acylsulfonamide class of NaV1.7 inhibitors, exemplified by the clinical development candidate GDC-0310, has been based solely on a single co-crystal structure of an arylsulfonamide inhibitor bound to voltage-sensing domain 4 (VSD4). To advance inhibitor design targeting the NaV1.7 channel, we pursued high-resolution ligand-bound NaV1.7-VSD4 structures using cryogenic electron microscopy (cryo-EM). Here, we report that GDC-0310 engages the NaV1.7-VSD4 through an unexpected binding mode orthogonal to the arylsulfonamide inhibitor class binding pose, which identifies a previously unknown ligand binding site in NaV channels. This finding enabled the design of a novel hybrid inhibitor series that bridges the aryl- and acylsulfonamide binding pockets and allows for the generation of molecules with substantially differentiated structures and properties. Overall, our study highlights the power of cryo-EM methods to pursue challenging drug targets using iterative and high-resolution structure-guided inhibitor design This work also underscores an important role of the membrane bilayer in the optimization of selective NaV channel modulators targeting VSD4.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. The NaV1.7-NaVPas/GNE-3565 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0R and EMDB entry ID EMD-28778, respectively. The NaV1.7-NaVPas/GDC-0310 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0Q and EMDB entry ID EMD-28777, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0S and EMDB entry ID EMD-28779, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0P and EMDB entry ID EMD-28776, respectively.

Article and author information

Author details

  1. Marc Kschonsak

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Christine C Jao

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Christopher P Arthur

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  4. Alexis L Rohou

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  5. Philippe Bergeron

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  6. Daniel F Ortwine

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Steven J McKerrall

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  8. David H Hackos

    Neuroscience, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Lunbin Deng

    Neuroscience, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  10. Jun Chen

    Biochemical and Cellular Pharmacology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Tianbo Li

    Biochemical and Cellular Pharmacology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Tianbo Li, Genentech employee.
  12. Peter S Dragovich

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  13. Matthew Volgraf

    Discovery Chemistry, Genentech, Inc, South San Francsico, United States
    Competing interests
    No competing interests declared.
  14. Matthew R Wright

    Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  15. Jian Payandeh

    Structural Biology, Genentech, Inc, South San Francisco, United States
    For correspondence
    jpayandeh@exelixis.com
    Competing interests
    No competing interests declared.
  16. Claudio Ciferri

    Structural Biology, Genentech, Inc, South San Francisco, United States
    For correspondence
    ciferri.claudio@gene.com
    Competing interests
    Claudio Ciferri, MK, CCJ, ALR, DFO, DHH, LD, JC, PSD, MW, CC and JCT are Genentech employees. All authors declare no competing financial interest..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0804-2411
  17. John C Tellis

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    For correspondence
    tellis.john@gene.com
    Competing interests
    No competing interests declared.

Funding

Genentech

  • Marc Kschonsak
  • Christine C Jao
  • Christopher P Arthur
  • Alexis L Rohou
  • Philippe Bergeron
  • Daniel F Ortwine
  • Steven J McKerrall
  • David H Hackos
  • Lunbin Deng
  • Jun Chen
  • Tianbo Li
  • Matthew Volgraf
  • Matthew R Wright
  • Jian Payandeh
  • Claudio Ciferri
  • John C Tellis

N/A

Copyright

© 2023, Kschonsak et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,081
    views
  • 623
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marc Kschonsak
  2. Christine C Jao
  3. Christopher P Arthur
  4. Alexis L Rohou
  5. Philippe Bergeron
  6. Daniel F Ortwine
  7. Steven J McKerrall
  8. David H Hackos
  9. Lunbin Deng
  10. Jun Chen
  11. Tianbo Li
  12. Peter S Dragovich
  13. Matthew Volgraf
  14. Matthew R Wright
  15. Jian Payandeh
  16. Claudio Ciferri
  17. John C Tellis
(2023)
Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
eLife 12:e84151.
https://doi.org/10.7554/eLife.84151

Share this article

https://doi.org/10.7554/eLife.84151

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Cristina Paissoni, Sarita Puri ... Carlo Camilloni
    Research Article

    Both immunoglobulin light-chain (LC) amyloidosis (AL) and multiple myeloma (MM) share the overproduction of a clonal LC. However, while LCs in MM remain soluble in circulation, AL LCs misfold into toxic-soluble species and amyloid fibrils that accumulate in organs, leading to distinct clinical manifestations. The significant sequence variability of LCs has hindered the understanding of the mechanisms driving LC aggregation. Nevertheless, emerging biochemical properties, including dimer stability, conformational dynamics, and proteolysis susceptibility, distinguish AL LCs from those in MM under native conditions. This study aimed to identify a2 conformational fingerprint distinguishing AL from MM LCs. Using small-angle X-ray scattering (SAXS) under native conditions, we analyzed four AL and two MM LCs. We observed that AL LCs exhibited a slightly larger radius of gyration and greater deviations from X-ray crystallography-determined or predicted structures, reflecting enhanced conformational dynamics. SAXS data, integrated with molecular dynamics simulations, revealed a conformational ensemble where LCs adopt multiple states, with variable and constant domains either bent or straight. AL LCs displayed a distinct, low-populated, straight conformation (termed H state), which maximized solvent accessibility at the interface between constant and variable domains. Hydrogen-deuterium exchange mass spectrometry experimentally validated this H state. These findings reconcile diverse experimental observations and provide a precise structural target for future drug design efforts.

    1. Structural Biology and Molecular Biophysics
    Kingsley Y Wu, Ta I Hung, Chia-en A Chang
    Research Article

    PROteolysis TArgeting Chimeras (PROTACs) are small molecules that induce target protein degradation via the ubiquitin-proteasome system. PROTACs recruit the target protein and E3 ligase; a critical first step is forming a ternary complex. However, while the formation of a ternary complex is crucial, it may not always guarantee successful protein degradation. The dynamics of the PROTAC-induced degradation complex play a key role in ubiquitination and subsequent degradation. In this study, we computationally modelled protein complex structures and dynamics associated with a series of PROTACs featuring different linkers to investigate why these PROTACs, all of which formed ternary complexes with Cereblon (CRBN) E3 ligase and the target protein bromodomain-containing protein 4 (BRD4BD1), exhibited varying degrees of degradation potency. We constructed the degradation machinery complexes with Culling-Ring Ligase 4A (CRL4A) E3 ligase scaffolds. Through atomistic molecular dynamics simulations, we illustrated how PROTAC-dependent protein dynamics facilitating the arrangement of surface lysine residues of BRD4BD1 into the catalytic pocket of E2/ubiquitin cascade for ubiquitination. Despite featuring identical warheads in this PROTAC series, the linkers were found to affect the residue-interaction networks, and thus governing the essential motions of the entire degradation machine for ubiquitination. These findings offer a structural dynamic perspective on ligand-induced protein degradation, providing insights to guide future PROTAC design endeavors.